Short answer
Pacira BioSciences, Inc. (PCRX) filed its Q3 2025 10-Q quarterly report on Nov 6, 2025 for the quarter ended Sep 30, 2025. Quarterly revenue was $180M (up 6.5% year over year) with net income of $5M.
Q3 2025 key financials · XBRL
- Revenue
- $180M
- +6.5% YoY · −0.9% QoQ
- Net income
- $5M
- +103.8% YoY · +212.1% QoQ
- Operating margin
- 3.5%
- EPS (diluted)
- $0.12
- +103.9% YoY · +220.0% QoQ
Source: XBRL data from the Pacira BioSciences, Inc. (PCRX) Q3 2025 10-Q on SEC EDGAR. USD.
Pacira BioSciences, Inc. Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- New risk: Settlement with eVenus ANDA Filers allows limited generic sales starting early 2030, volume capped rising from high single-digit to high thirties % by late 2030s
- Updated risk: Patent infringement litigation expanded with new suits filed in Dec 2024, and new declaratory judgment action by eVenus ANDA Filers in 2025
- Regulatory risk: Multiple Paragraph IV certifications received in Oct 2025 from Chinese generic firms challenging EXPAREL patents, triggering 45-day lawsuit window
- Operational risk: Competitors with alternative delivery systems for bupivacaine threaten commercial opportunity by avoiding pMVL patent scope
- Financial risk: $7.0 million settlement payment to eVenus ANDA Filers recognized for litigation resolution and future royalty/license agreements
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Pacira BioSciences, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.